The private equity firm’s life sciences unit backs start-up with rights to five programs

Start-up’s anti-CD36 mAb turns immune cells against cancers

BioCentury’s roundup of translational innovation also includes a new target for arrhythmia and four papers with links to newcos

BioCentury’s weekly roundup of biopharma deals, Jan. 30- Feb. 5

Companies face growing challenges in deciding whether to advance an immuno-oncology program based on early Phase I data

Plus: EU orders Illumina to unwind Grail acquisition and updates from Pfizer, Lilly, PepGen, VitaDAO and Synerkine